MONDAY, APRIL 24, 2017

7:00 AM-5:00 PM  Registration  Grand Ballroom Foyer
7:00-8:00 AM  Poster Set-Up  Grand Ballroom Foyer
7:30-8:30 AM  Continental Breakfast  Grand Ballroom Foyer

8:30-9:30 AM  Opening Keynote | K1  Grand Ballroom E-H
Moderator: Walter A. Orenstein, MD
Emory University
Atlanta, GA

Greatest Vaccinology Discoveries of the Last Decade and Future Predictions
Stanley A. Plotkin, MD
University of Pennsylvania
Vaxconsult
Doylestown, PA

9:30-11:00 AM  Symposium 1: Challenges Implementing the
World’s First Licensed Dengue Vaccine | S1-0  Grand Ballroom E-H
Moderator: Cristina G. Cassetti, PhD
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Rockville, MD

9:40-9:55 AM | S1-1
Long Road to Preventing Dengue Disease by Vaccination, and Future Prospects
Duane J. Gubler, ScD, MS
Duke National University of Singapore Medical School
Singapore

9:55-10:10 AM | S1-2
Biology of Antibody-Enhanced Dengue Disease: Evidence of Increased Risk
After CYD-TDV Vaccination
Scott B. Halstead, MD
International Vaccine Institute
Bethesda, MD
10:10-10:25 AM | S1-3
Optimal Use of the First Licensed Dengue Vaccine: Balancing Benefit Against Potential Risks
Neil M. Ferguson, PhD
Imperial College London
London, England

10:25-10:40 AM | S1-4
Maximizing Benefit and Minimizing Risk for the World’s First Licensed Dengue Vaccine: CYD-TDV
Timothy P. Endy, MD, MPH
State University of New York, Upstate Medical University
Syracuse, NY

10:40-11:00 AM
Questions and Answers

11:00-11:30 AM
Coffee Break
Grand Ballroom Foyer

11:30-1:00 PM
Symposium 2: Development and Approval Pathways of Vaccines For the Prevention of Emerging Infectious Diseases | S2-0 CE
Moderator: Kathleen M. Neuzil, MD, MPH
University of Maryland School of Medicine
Baltimore, MD

11:40-11:55 AM | S2-1
Epidemiology, Disease Burden, and Population Targets for Zika Vaccine
Marcos A. Espinal, MD, DrPH, MPH
Pan American Health Organization
Washington, DC

11:55 AM-12:10 PM | S2-2
BARDA Perspective about Challenges and Opportunities in Developing EID Vaccines
Ruben O. Donis, PhD
Biomedical Advanced Research and Development Authority
US Department of Health & Human Services
Washington, DC

12:10-12:25 PM | S2-3
Development and Approval Pathways for Vaccines to Prevent Emerging Infectious Diseases: FDA Regulatory Perspective
Marion F. Gruber, PhD
US Food and Drug Administration
Silver Spring, MD
12:25-12:40 PM | S2-4  
Rapid Development of Candidate Zika Vaccines  
Barney S. Graham, MD, PhD  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
Bethesda, MD

12:40-1:00 PM  
Questions and Answers

1:00-2:00 PM  
Lunch (on your own)

2:00-4:00 PM  
Symposium 3: Therapeutic Vaccines for Addiction | S3-0  
Grand Ballroom E-H  
Moderator: Raphael Simon, PhD  
University of Maryland School of Medicine  
Baltimore, MD

2:10-2:40 PM | S3-1  
Vaccination as a Means to Mitigate Drug Addiction  
Kim D. Janda, PhD  
The Scripps Research Institute  
La Jolla, CA

2:40-3:10 PM | S3-2  
Development of Vaccines to Prevent and Treat Addiction to  
Cocaine and Opiate Drugs  
Thomas R. Kosten, MD  
Baylor College of Medicine  
Houston, TX

3:10-3:40 PM | S3-3  
Treating Cocaine Addiction with Viral Vector for Cholinesterase in Mice, Rats,  
and Rhesus Monkeys  
William S. Brimijoin, PhD  
Mayo Clinic and Foundation  
Rochester, MN

3:40-4:00 PM  
Questions and Answers

4:00-4:30 PM  
Coffee Break  
Grand Ballroom Foyer
PROGRAM AGENDA

4:30-5:30 PM | Symposium 4: Human Challenge Models in Vaccine Development | S4-0 (CE)
Moderator: Marion F. Gruber, PhD
US Food and Drug Administration
Silver Spring, MD

4:35-4:55 PM | S4-1
Scientific and Regulatory Aspects of Such Studies of Vaccines
Wellington Sun, MD
US Food and Drug Administration
Silver Spring, MD

4:55-5:15 PM | S4-2
FDA Licensure of a Cholera Vaccine as a Result of Pivotal Efficacy Derived from Human Challenges
Wilbur H. Chen, MD, MS
University of Maryland School of Medicine
Baltimore, MD

5:15-5:30 PM
Questions and Answers

5:30-6:30 PM | Welcome Reception & Poster Presentations

TUESDAY, APRIL 25, 2017

7:00 AM-5:00 PM | Registration
Grand Ballroom Foyer

7:30-8:30 AM | Poster Presentations & Continental Breakfast
Grand Ballroom Foyer

8:30-9:30 AM | Mary Lou Clements-Mann Memorial Lecture in Vaccine Sciences | K2 (CE)
Moderator: Myron M. Levine, MD, DTPH
University of Maryland School of Medicine
Baltimore, MD

D.A. Henderson Tribute: Legacy of Eradication Through Vaccines
William H. Foege, MD, MPH
Bill & Melinda Gates Foundation
Seattle, WA

9:30-10:00 AM | Coffee Break
Grand Ballroom Foyer
Concurrent Sessions

**Oral Abstracts 1: Epidemiology and Burden of Disease | OA1-0**

**Moderator: Cyril G. Gay, DVM, PhD**
**Grand Ballroom E**

**US Department of Agriculture**
**Beltville, MD**

**10:00-10:15 AM | OA1-1**

*Using the 4 Pillars™ Practice Transformation Program to Increase Adolescent Human Papillomavirus, Meningococcal, and Tetanus-Diphtheria-Pertussis Vaccination*

Richard K. Zimmerman, MD, MPH, MA, MS
University of Pittsburgh
Pittsburgh, PA

**10:15-10:30 AM | OA1-2**

*Antibody Responses to Zika Virus in Primary and Secondary Flavivirus Infections*

Muktha S. Natrajan, PhD, MPH
Emory University
Atlanta, GA

**10:30-10:45 AM | OA1-3**

*Modeling Reveals How Vaccination Could Significantly Reduce Hepatitis C Transmission via Syringe Sharing*

Marian E. Major, PhD
US Food and Drug Administration
Silver Spring, MD

**10:45-11:00 AM | OA1-4**

*Influence of e-Health Text Messages Linked to Health Portal on College Students' Influenza Vaccine Rate*

Catherine A. Sharbaugh
Haverford College
Haverford, PA

**11:00-11:15 AM | OA1-5**

*The Global Burden of Lower Respiratory Infections: Results from the Global Burden of Disease Study 2015*

Chris E. Troeger, MPH
University of Washington
Seattle, WA
PROGRAM AGENDA

11:15-11:30 AM | OA1-6
The Global Burden of Shigella and Enterotoxigenic E. coli Diarrhea
Ibrahim A. Khalil, MD, MPH
University of Washington
Seattle, WA

Oral Abstracts 2: Preclinical and Clinical Trials | OA2-0
Moderator: Alison C. Mawle, PhD
Centers for Disease Control and Prevention
Atlanta, GA

10:00-10:15 AM | OA2-1
A Non-Glycosylated G Protein Vaccine Protects Against Homologous and Heterologous Respiratory Syncytial Virus Challenge in Both Mice and Cotton Rats
Surender Khurana, PhD
US Food and Drug Administration
Silver Spring, MD

10:15-10:30 AM | OA2-2
“Immune Focused” Influenza Vaccines Provide Better, Long-Lasting Cross-Protective Immunity Compared to IIV Against Pandemic H5 & H7 Highly Pathogenic Influenza Viruses
Surender Khurana, PhD
US Food and Drug Administration
Silver Spring, MD

10:30-10:45 AM | OA2-3
Sci-B-Vac, A Third Generation Hepatitis B Vaccine That Elicits Rapid and Robust Seroprotection in Adults
Francisco J. Diaz Mitoma, MD, PhD, FRCPC
VBI Vaccines, Inc.
Ottawa, Canada

10:45-11:00 AM | OA2-4
The IVAX Toolkit: Accelerating and Advancing Human and Animal Vaccine Design in Silico
Frances E. Terry, MPH
EpiVax
Providence, RI

11:00-11:15 AM | OA2-5
Genome-Wide Association Mapping of the Antibody Response to Diphtheria-Tetanus-Acellular Pertussis Vaccine in Mice
Yung-Yi C. Mosley, BVM, MS, PhD
Purdue University
West Lafayette, IN
11:15-11:30 AM | OA2-6
Vu D. Thiem, MD, PhD
National Institute of Hygiene and Epidemiology
Hanoi, Vietnam

11:30 AM-12:00 PM Coffee Break Grand Ballroom Foyer

12:00-1:00 PM Awards Luncheon Grand Ballroom E-H
Moderator: Walter A. Orenstein, MD
Emory Vaccine Center
Emory University
Atlanta, GA

12:10-12:30 PM Robert Austrian Memorial Lecture | AL-1
Thinking Outside the Bug: An Admiral's Reflections on the Captain of the Men of Death
Anne Schuchat, MD (RADM, USPHS)
Centers for Disease Control and Prevention
Atlanta, GA

12:30-12:40 PM Dr. Charles Mérieux Award for Achievement in Vaccinology and Immunology | AL-2
Samuel L. Katz, MD
Duke University School of Medicine
Durham, NC

12:40-1:00 PM Maurice R. Hilleman Early-Stage Career Investigator Award | AL-3

1:00-1:30 PM Coffee Break Grand Ballroom Foyer

1:30-3:00 PM Concurrent Sessions  

Oral Abstracts 3: New and Emerging Vaccines (Part 1) | OA3-0  
Moderator: H. Keipp B. Talbot, MD, MPH
Vanderbilt University School of Medicine
Nashville, TN
1:30-1:45 PM | OA3-1
Evolution of HIV-1 Env Open Trimer Conformation Driven by Peptide Fusion Inhibitor Resistance
Paul W. Keller, PhD
US Food and Drug Administration
Silver Spring, MD

1:45-2:00 PM | OA3-2
Effect of Influenza Vaccination on Lymphocyte Mirna Profiles
Richard B. Kennedy, PhD
Mayo Clinic and Foundation
Rochester, MN

2:00-2:15 PM | OA3-3
Identification of Highly Conserved Influenza a HLA-A2 and HLA-DR-restricted T Cell Epitopes Capable of Inducing Robust Heterotypic Protective Immunity
Daniel F. Hoft, MD, PhD
Saint Louis University
St. Louis, MO

2:15-2:30 PM | OA3-4
Serum Antibody Profiling Following Vaccination with an Adjuvanted Thermostable Subunit Antigen Reveals a Possible Correlate of Immunity to Ricin Toxin
Jennifer L. Yates, PhD
Heath Research Inc.
Albany, NY

2:30-2:45 PM | OA3-5
Protection of Horse Foals Against the Tuberculosis-Like Pathogen Rhodococcus Equi via Conjugate Vaccine (AV0328)-Induced Maternal Antibody to Poly-N-Acetyl glucosamine
Gerald B. Pier, PhD
Brigham & Women’s Hospital
Boston, MA

2:45-3:00 PM | OA3-6
Viral Vector-Based Prime/boost Regimen to Maximize Tissue-Resident Memory T Cell Responses for Therapeutic Vaccination Against HPV Cervicovaginal Neoplasia
Nicolas Çuburu, PhD
National Institutes of Health
National Cancer Institute
Bethesda, MD
Oral Abstracts 4: Vaccine Safety (Part 1) | OA4-0  
Moderator: Gregory A. Poland, MD  
Mayo Clinic and Foundation  
Rochester, MN  

1:30-1:45 PM | OA4-1  
Mapping the Morality of Vaccine Hesitance: Associations of Moral Foundation Values with Vaccine Hesitance  
Avnika B. Amin  
Emory University  
Atlanta, GA  

1:45-2:00 PM | OA4-2  
Zika in the United States: Transmission and Strategies for Control  
L. Beryl Guterman  
Emory University  
Atlanta, GA  

2:00-2:15 PM | OA4-3  
Safety of MenB-FHbp, a Meningococcal Serogroup B Vaccine, in US Young Adults: Results from a Phase 3 Study  
John L. Perez, MD  
Pfizer Vaccine Clinical Research  
Collegeville, PA  

2:15-2:30 PM | OA4-4  
Safety of MenB-FHbp, a Meningococcal Serogroup B Vaccine, in US Adolescents: Results from a Phase 3 Study  
John L. Perez, MD  
Pfizer Vaccine Clinical Research  
Collegeville, PA  

2:30-2:45 PM | OA4-5  
Genetic Diversity of Non-Structural Asibi/17d Mutant Yellow Fever Viruses  
Natalie D. Collins, MPH  
University of Texas Medical Branch  
Galveston, TX  

2:45-3:00 PM | OA4-6  
Tumorigenicity of Spontaneously Immortalized Cells Used in Vaccine Manufacture: Responsiveness to Matrigel as a Possible Trait for Tumorigenicity Characterization  
Haruhiko Murata, MD, PhD  
US Food and Drug Administration  
Silver Spring, MD
PROGRAM AGENDA

20th annual conference on Vaccine Research

3:00-3:30 PM  Coffee Break  Grand Ballroom Foyer

3:30-5:00 PM  Concurrent Sessions

Oral Abstracts 5: New and Emerging Vaccines (Part 2) | OA5-0
Moderator: Bruce G. Weniger, MD, MPH
Chiang Mai University
Chiang Mai, Thailand

3:30-3:45 PM  OA5-1
Willingness to Pay for an Ebola Vaccine Among a US National Sample During the Height of the 2014-2016 West African Ebola Outbreak
Julia E. Painter, PhD, MPH
George Mason University
Fairfax, VA

3:45-4:00 PM  OA5-2
Advancing the Clinical Development of GEN-003, a Therapeutic Vaccine for Recurrent Genital Herpes
Thomas C. Heineman, MD, PhD
Genocea Biosciences
Cambridge, MA

4:00-4:15 PM  OA5-3
A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity Against *Trypanosoma cruzi*
Nisha J. Garg, PhD, MBA
University of Texas Medical Branch
Galveston, TX

4:15-4:30 PM  OA5-4
Immune Response and Viral Persistence in Acute Human Zika Virus Infection – a Preliminary Report
Lilin Lai, MD
Emory University
Atlanta, GA

4:30-4:45 PM  OA5-5
Tools to Characterize the Immune Response to Zika Virus (ZIKV): Reporter Virus Particles, Anti-ZIKV MAbs, and Antibody Epitope Mapping
Edgar Davidson, PhD
Integral Molecular
Philadelphia, PA
4:45-5:00 PM | OA5-6

**Human Antibody Repertoire Following VSV-Ebola Vaccination Identifies Novel Targets and Virus Neutralizing IgM Antibodies**
Surender Khurana, PhD
US Food and Drug Administration
Silver Spring, MD

**Oral Abstracts 6: Vaccine Safety (Part 2) | OA6-1**

Moderator: Karin Bok, MS, PhD
US Department of Health and Human Services
Washington, DC

Grand Ballroom F-H

3:30-3:45 PM | OA6-1

**Nonclinical Investigations into the Reduced Effectiveness of the H1N1pdm09 Component of the Live Attenuated Influenza Vaccine**
Oliver E. Dibben, PhD
MedImmune
Liverpool, England

3:45-4:00 PM | OA6-2

Lakshmi Sukumaran, MD, MPH
Centers for Disease Control and Prevention
Atlanta, GA

4:00-4:15 PM | OA6-3

**Recommended Immunization Schedule and All-Cause Mortality**
Natalie L. McCarthy, MPH
Centers for Disease Control and Prevention
Atlanta, GA

4:15-4:30 PM | OA6-4

**Adverse Events Following Quadrivalent Meningococcal CRM-Conjugate Vaccine Reported to the Vaccine Adverse Event Reporting System (VAERS), 2010-2015**
Tanya R. Myers, PhD, MS
Emory University
Centers for Disease Control and Prevention
Atlanta, GA

4:30-4:45 PM | OA6-5

**Feasibility of Examining Potential Mechanisms for Intussusception Following Rotavirus Vaccination in Infants 6-13 Weeks of Age**
Mary A. Staat, MD, MPH
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH
20TH ANNUAL CONFERENCE ON

PROGRAM AGENDA

4:45-5:00 PM  |  OA6-6
Adverse Events Following Purified Chick Embryo Cell (PCEC, Rabavert®) Vaccine in the Vaccine Adverse Event Reporting System, 2006-2015
Pedro L. Moro, MD, MPH
Centers for Disease Control and Prevention
Atlanta, GA

5:30-7:00 PM  |  Grand Ballroom E
Hilleman: A Perilous Quest to Save the World’s Children
Movie Screening followed by Q&A with Producer
Paul A. Offit, MD
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

WEDNESDAY, APRIL 26, 2017

7:00 AM-1:00 PM  |  Grand Ballroom Foyer
Registration

7:00-8:00 AM  |  Grand Ballroom Foyer
Continental Breakfast

7:00-7:45 AM  |  Linden Oak (lower level)
Dr. Richard J. Duma Meet the Experts Breakfast Sessions
Maximizing Benefit and Minimizing Risk for the World’s First Licensed Dengue Vaccine: CYD-TDV
Timothy P. Endy, MD, MPH
State University of New York, Upstate Medical University
Syracuse, NY

Development and Approval Pathways for Vaccines to Prevent Emerging Infectious Diseases: FDA Regulatory Perspective
Marion F. Gruber, PhD
US Food and Drug Administration
Silver Spring, MD

Biology of Antibody-Enhanced Dengue Disease: Evidence of Increased Risk After CYD-TDV Vaccination
Scott B. Halstead, MD
International Vaccine Institute
Bethesda, MD

How to Get Published: Writing Effective Journal Articles
Gregory A. Poland, MD
Mayo Clinic and Foundation
Rochester, MN

Post-licensure Vaccine Safety Monitoring
Tom T. Shimabukuro, MD, MPH, MBA
Centers for Disease Control and Prevention
Atlanta, GA
Clinical Development of Synthetic DNA Vaccines: Advances in the Technology
David B. Weiner, PhD
Wistar Institute
Philadelphia, PA

8:00-10:00 AM  Symposium 5: Vaccine Innovations | S5-0  
Moderator: Hana Golding, PhD
US Food and Drug Administration
Silver Spring, MD

8:10-8:30 AM | S5-1  
Clinical Development of Synthetic DNA Vaccines: Advances in the Technology
David B. Weiner, PhD
Wistar Institute
Philadelphia, PA

8:30-8:50 AM | S5-2  
mRNA-Based Vaccines Against HIV and Other Pathogens
Drew Weissman, MD, PhD
University of Pennsylvania
Philadelphia, PA

8:50-9:10 AM | S5-3  
Structure-Based Immunogen Design for Flavivirus Vaccines
Felix A. Rey, PhD
Institut Pasteur
Paris, France

9:10-9:30 AM | S5-4  
Recoding Structural Glycoprotein E2 in Classical Swine Fever Virus (CSFV) and Its Potential Use as a Vaccine Candidate
Lauro Velazquez, DVM, MS
Plum Island Animal Disease Center
Orient Point, NY

9:30-10:00 AM  Questions and Answers

10:00-10:30 AM  Coffee Break
10:30 AM-12:30 PM  Symposium 6: Evaluating Vaccine Safety during Public Health Emergencies | S6-0
Moderator: Saad B. Omer, MBBS, MPH, PhD
Emory University & Emory Vaccine Center
Atlanta, GA

10:40-11:10 AM  S6-1
Systematic Observational Method for Narcolepsy and Influenza Immunization Assessment (Somnia): Risk of Narcolepsy Following Adjuvanted 2009 H1N1 Influenza Vaccines
Tom T. Shimabukuro, MD, MPH, MBA
Centers for Disease Control and Prevention
Atlanta, GA

11:10-11:40 AM  S6-2
Maintaining Public Confidence in Vaccines During a Pandemic
Daniel A. Salmon, PhD
Johns Hopkins Bloomberg School of Public Health
Baltimore, MD

11:40 AM-12:10 PM  S6-3
Monitoring Influenza Vaccine Safety in Sentinel/Prism
Katherine Yih, PhD, MPH
Harvard Medical School and Harvard Pilgrim Health Care Institute
Boston, MA

12:10-12:30 PM  Questions and Answers

12:30-1:30 PM  Lunch (on your own)
1:30-2:30 PM

Closing Keynote

Vaccines to Fight Emerging Infectious Diseases: Use of Novel Platform Technologies | K3

(Note: No CE will be awarded for this session)

Moderator: Phyllis A. Arthur, MBA
Biotechnology Innovation Organization
Washington, DC

Presenters:
Marc-André D’Aoust, PhD
Medicago
Quebec, Canada

Christopher R. Heery, MD
Bavarian Nordic A/S
Washington, DC

Jeffrey B. Ulmer, PhD
GSK Vaccines
Washington, DC

David B. Weiner, PhD
Wistar Institute
Philadelphia, PA